VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

Company Engages Stillwater Capital to Explore Strategic M&A Opportunities Amid Growing Demand for Objective Assessments TORONTO — VoxNeuro Inc. (the Company) today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Cognitive Function Neuroimaging (cfNI) software, a prescription-use Software-as-a-Medical-Device (SaMD) that provides digital, post-hoc statistical analysis of electroencephalography (EEG), including […]